1. Home
  2. ENTA vs DOMO Comparison

ENTA vs DOMO Comparison

Compare ENTA & DOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$15.87

Market Cap

486.3M

Sector

Health Care

ML Signal

HOLD

Logo Domo Inc. Class B

DOMO

Domo Inc. Class B

HOLD

Current Price

$8.42

Market Cap

477.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
DOMO
Founded
1995
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
486.3M
477.0M
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
ENTA
DOMO
Price
$15.87
$8.42
Analyst Decision
Strong Buy
Buy
Analyst Count
5
9
Target Price
$20.40
$15.22
AVG Volume (30 Days)
370.9K
1.1M
Earning Date
02-09-2026
12-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$65,324,000.00
$318,002,000.00
Revenue This Year
$0.99
$2.28
Revenue Next Year
$0.19
$2.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.09
$6.01
52 Week High
$17.15
$18.49

Technical Indicators

Market Signals
Indicator
ENTA
DOMO
Relative Strength Index (RSI) 60.04 31.98
Support Level $14.07 $8.63
Resistance Level $17.15 $9.22
Average True Range (ATR) 0.95 0.39
MACD -0.01 0.10
Stochastic Oscillator 56.71 5.78

Price Performance

Historical Comparison
ENTA
DOMO

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

Share on Social Networks: